Aaron Ring

AI won’t revolutionize drug discovery for Big Pharma. They don’t need it. Pharma has been making remarkable biologic molecules for decades. Not just simple blockers, but a dizzying array of sophisticated therapeutics. Bispecific and multispecific antibodies. T cell engagers. “Masked” molecules that activate specifically in the tumor microenvironment. ATP- and pH-controlled antibodies. Binders to integral membrane proteins like GPCRs and... Read More